Abstract: The invention relates to polymers comprising NOS agonists and one or more monomers selected from the group consisting of lactide, glycolide and epsiloncaprolactone, wherein the NOS agonist is incorporated as repeating monomer units into the body or backbone of the polymer are disclosed. The NOS agonist may comprise one or more carboxylic acid groups and one or more alkylhydroxy groups. In another embodiment, the NOS agonist may comprise a carboxylic acid group and an alkylhydroxy group that can be joined to form a lactone containing cyclic ring. In another embodiment, the NOS agonist comprises HMG CoA reductase inhibitor or statin.

Abstract: The present invention relates to a bioresorbable scaffold for a vascular stent comprising a nitric oxide agonist and a polymer comprising a lactide, a glycolide and a lactone. The nitric oxide agonist is a statin or a HMG CoA reductase inhibitor. The nitric oxide agonist may be coated on the polymer, incorporated within the polymer or chemically bonded to the polymer. The invention also relates to a method for treating atherothrombosclerotic occlusive disease of an artery comprising implanting into the artery a stent with a bioresorbable scaffold comprising a nitric oxide agonist and a polymer comprising a lactide, a glycolide and a lactone, wherein the nitric oxide agonist is exuded from or released from the bioresorbable scaffold.

Abstract: Resorbable biomaterials including polystatin polymers and devices including the resorbable biomaterials are described. Methods of making the resorbable biomaterials and devices including resorbable biomaterials are also described.

Abstract: The present invention relates to a bioresorbable scaffold for a vascular stent comprising a nitric oxide agonist and a polymer comprising a lactide, a glycolide and a lactone. The nitric oxide agonist is a statin or a HMG CoA reductase inhibitor. The nitric oxide agonist may be coated on the polymer, incorporated within the polymer or chemically bonded to the polymer. The invention also relates to a method for treating atherothrombosclerotic occlusive disease of an artery comprising implanting into the artery a stent with a bioresorbable scaffold comprising a nitric oxide agonist and a polymer comprising a lactide, a glycolide and a lactone, wherein the nitric oxide agonist is exuded from or released from the bioresorbable scaffold.

Abstract: Novel combinations comprising HMG CoA reductase inhibitors, or statins, with partial fatty acid oxidation inhibitors (pFOXi), and methods for their use, are disclosed. These combinations are useful in preventing or reducing the risk of developing diabetes which results from therapy with a statin.

Abstract: A sustained release formulation of L-arginine alone or in combination with an agent which enhances the biotransformation of L-arginine into NO is described herein. FIG. 1A shows a schematic representation of proposed L-arginine dependent and independent pathways.

Abstract: Embodiments of the present invention include compositions and pharmaceutical compositions comprising citrulline and Hmg-CoA reductase inhibitors. Further embodiments relate to the use of such composition treat subjects and stimulating nitric oxide synthase.

Abstract: A sustained release formulation of L-arginine alone or in combination with an agent which enhances the biotransformation of L-arginine into NO is described herein.

Abstract: Vessels are treated with a mixture of L-arginine and an agent which enhances the biotransformation of L-arginine into NO. The incidents associated with restenosis are expected to be substantially reduced and prevented providing for a reduced incidence of restenosis as a result of the injury.

Abstract: Vessels are treated with a mixture of L-arginine and an agent which enhances the biotransformation of L-arginine into NO. The incidents associated with restenosis are expected to be substantially reduced and prevented providing for a reduced incidence of restenosis as a result of the injury.

Abstract: A sustained release formulation of L-arginine alone or in combination with an agent which enhances the biotransformation of L-arginine into NO is described herein. FIG. 1A shows a schematic representation of proposed L-arginine dependent and independent pahtways.

Abstract: Therapeutic mixtures of statins alone or in combination with L-arginine are described herein.

Abstract: A method for treating a subject who would benefit from increased nitric oxide production comprising administering inhibitors of Hmg-CoA-Reductase is disclosed for the treatment of diseases related to endothelial dysfunction.

Abstract: Vessels are treated with a mixture of L-arginine and an agent which enhances the biotransformation of L-arginine into NO. The incidents associated with restenosis are expected to be substantially reduced and prevented providing for a reduced incidence of restenosis as a result of the injury.

Abstract: A therapeutic mixture comprised of L-arginine and angiogenic growth factors is disclosed for the treatment of diseases related to endothelial dysfunction.

Abstract: A therapeutic mixture comprised of L-arginine and inhibitors of Hmg--CoA-Reductase is disclosed for the treatment of diseases related to endothelial dysfunction, wherein the endothelial dysfunction is relieved by stimulating the constitutive form of nitric oxide synthase (cNOS) to produce native nitric oxide (NO).